Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. ET. Investors and interested parties can access the live webcast through the Events section of Cartesian's website at www.cartesiantherapeutics.com. An archived replay will be available for a time after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RNAC declined 5.24%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET.
A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
When is Cartesian Therapeutics (RNAC) presenting at the Needham Healthcare Conference 2025?
How can investors watch Cartesian Therapeutics' (RNAC) Needham Conference presentation?
What is the main focus of Cartesian Therapeutics' (RNAC) research and development?
What type of event will RNAC participate in at the Needham Healthcare Conference?
